近日,在支付了 4 亿美元首付款后,安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源:协和麒麟官网Rocatinlimab 是一款OX40 单抗,基于协和麒麟专有的 POTELLIGENT 技术开发,降低了抗体糖链结构中的岩藻糖成分,进而增强了其抗体依赖性细胞毒性作用(ADCC)。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月,安进引进了...
Source Link近日,在支付了 4 亿美元首付款后,安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源:协和麒麟官网Rocatinlimab 是一款OX40 单抗,基于协和麒麟专有的 POTELLIGENT 技术开发,降低了抗体糖链结构中的岩藻糖成分,进而增强了其抗体依赖性细胞毒性作用(ADCC)。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月,安进引进了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.